These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 14553822

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH.
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
    Böger RH, Zoccali C.
    Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
    [Abstract] [Full Text] [Related]

  • 6. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R, Cibulka R, Rajdl D, Racek J.
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [Abstract] [Full Text] [Related]

  • 7. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH, Bode-Böger SM.
    Semin Thromb Hemost; 2000 Mar; 26(5):539-45. PubMed ID: 11129410
    [Abstract] [Full Text] [Related]

  • 8. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production.
    Pope AJ, Karuppiah K, Cardounel AJ.
    Pharmacol Res; 2009 Dec; 60(6):461-5. PubMed ID: 19682581
    [Abstract] [Full Text] [Related]

  • 9. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA.
    JPEN J Parenter Enteral Nutr; 2008 Dec; 32(6):613-21. PubMed ID: 18974239
    [Abstract] [Full Text] [Related]

  • 10. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R.
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [Abstract] [Full Text] [Related]

  • 11. The clinical significance of asymmetric dimethylarginine.
    Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA.
    Annu Rev Nutr; 2006 Jul; 26():203-28. PubMed ID: 16848705
    [Abstract] [Full Text] [Related]

  • 12. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V, Bianchi M, Pascale V, Ferrario P, Morelli F, Pascale W, Tomasoni L, Turiel M.
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
    Dayoub H, Rodionov RN, Lynch C, Cooke JP, Arning E, Bottiglieri T, Lentz SR, Faraci FM.
    Stroke; 2008 Jan; 39(1):180-4. PubMed ID: 18063827
    [Abstract] [Full Text] [Related]

  • 14. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
    Palm F, Onozato ML, Luo Z, Wilcox CS.
    Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3227-45. PubMed ID: 17933965
    [Abstract] [Full Text] [Related]

  • 15. Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study.
    Mügge A, Hanefeld C, Böger RH, CARDIAC study investigators.
    Atheroscler Suppl; 2003 Dec; 4(4):29-32. PubMed ID: 14664900
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
    Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S.
    Curr Pharm Des; 2008 Dec; 14(25):2613-8. PubMed ID: 18991678
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ADMA and hyperhomocysteinemia.
    Dayal S, Lentz SR.
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [Abstract] [Full Text] [Related]

  • 20. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
    Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP.
    Circulation; 1998 Nov 03; 98(18):1842-7. PubMed ID: 9799202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.